Marshall Wace LLP Has $44,000 Stock Holdings in Immunic, Inc. (NASDAQ:IMUX)

Marshall Wace LLP trimmed its holdings in Immunic, Inc. (NASDAQ:IMUX) by 20.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 39,621 shares of the company’s stock after selling 9,908 shares during the period. Marshall Wace LLP’s holdings in Immunic were worth $44,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in IMUX. Vanguard Group Inc. boosted its holdings in shares of Immunic by 100.7% in the 1st quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock valued at $4,480,000 after purchasing an additional 1,703,047 shares in the last quarter. Janus Henderson Group PLC bought a new position in shares of Immunic in the 1st quarter worth about $9,266,000. Ikarian Capital LLC raised its stake in Immunic by 258.3% during the 1st quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock worth $2,128,000 after buying an additional 1,162,378 shares during the period. Virtu Financial LLC purchased a new stake in shares of Immunic in the first quarter worth approximately $25,000. Finally, BVF Inc. IL purchased a new stake in shares of Immunic in the first quarter worth approximately $11,752,000. 51.82% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. B. Riley began coverage on Immunic in a report on Tuesday, August 27th. They issued a “buy” rating and a $6.00 target price for the company. Piper Sandler restated an “overweight” rating and set a $28.00 price target on shares of Immunic in a research report on Tuesday, July 16th. Leerink Partners reaffirmed an “outperform” rating and set a $5.00 price objective on shares of Immunic in a research note on Monday, September 9th. Leerink Partnrs raised Immunic to a “strong-buy” rating in a research note on Monday, September 9th. Finally, EF Hutton Acquisition Co. I raised Immunic to a “strong-buy” rating in a research note on Monday, September 16th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Immunic presently has an average rating of “Buy” and an average price target of $11.20.

Immunic Price Performance

NASDAQ IMUX opened at $1.40 on Monday. The firm has a market cap of $126.11 million, a price-to-earnings ratio of -0.77 and a beta of 1.84. The business has a 50-day moving average price of $1.49 and a 200-day moving average price of $1.34. Immunic, Inc. has a twelve month low of $0.95 and a twelve month high of $2.11.

Immunic (NASDAQ:IMUX) last posted its earnings results on Thursday, August 8th. The company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.02. During the same period in the previous year, the company earned ($0.54) earnings per share. Research analysts expect that Immunic, Inc. will post -0.92 EPS for the current fiscal year.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.